This is the whole document to my last post wuth a...

This is the whole document to my last post wuth a link.

www.heartfailure.it/download/guidelines.pdf

Page 1
Rationale and Process: International Society for Heart and LungTransplantation Guidelines for the Care of Cardiac TransplantCandidates—2006Mandeep R. Mehra, MD, Mariell Jessup, MD, Edoardo Gronda, MD, and Maria Rosa Costanzo, MDIn April 2005, the International Society for Heart andLung Transplantation (ISHLT) board sanctioned thedevelopment of a comprehensive set of guidelines forthe pre-transplant management of cardiac transplantcandidates. This mandate resulted from the recognitionthat current guidelines were either too old, lackeddetailed attention to the care of the cardiac transplantcandidate, or were not broad enough to be applicableto the international community of cardiac transplantphysicians and surgeons. To address these issues, threetask forces were assembled.TASK FORCESTask Force I: Listing Criteria for Heart Transplantation.Task Force II: Optimal Pharmacologic and Non-pharma-cologic Management of Cardiac Transplant Candi-dates: Approaches to Be Considered Before Trans-plant Evaluation.Task Force III: Heart Rhythm Considerations in HeartTransplant Candidates and Considerations for Ven-tricular Assist Devices.Each task force consisted of an international mix ofmembers, charged by their respective group chairs toreview and deliberate specific issues of importance tothis population. A 1-day-long workshop format meetingwas held in April 2005, during which the guidelineswere debated and consensus achieved. A summary ofthe key highlighted recommendations that evolvedfrom this meeting were presented at the closing plenaryof the ISHLT meeting in 2005. The comprehensiveguidelines were collated and edited to conform to astandard classification and strength of evidence.CLASSES OF RECOMMENDATIONClass I: Conditions for which there is evidence and/orgeneral agreement that a given procedure or treat-ment is beneficial, useful and effective.Class II: Conditions for which there is conflictingevidence and/or divergence of opinion about theusefulness/efficacy of a procedure or treatment.Class IIa: Weight of evidence/opinion is in favor ofusefulness/efficacy.Class IIb: Usefulness/efficacy is less well established byevidence/opinion.Class III: Conditions for which there is evidence and/orgeneral agreement that a procedure/treatment is notuseful/effective and in some cases may be harmful.LEVEL OF EVIDENCELevel of Evidence A: Data derived from multiple ran-domized clinical trials or meta-analyses.Level of Evidence B: Data derived from a single random-ized trial, or non-randomized studies.Level of Evidence C: Only consensus opinion of ex-perts, case studies or standard-of-care.Once completed, the entire document was rigorouslyreviewed by an independent international editorialcommittee (see Appendix) and changes made in accor-dance with the reviews. The editorial oversight com-mittee composition was blinded to the task force chairsand members. The revised final document was subse-quently submitted to the ISHLT board for review andapproval.It is our earnest hope that the rigor and multinationalnature of this guidelines document will be of use to theclinician caring for the cardiac transplant candidate.APPENDIXI. Task Force Members(a) Task Force I—Listing Criteria for Heart Transplantation:Mandeep R. Mehra—Chair (USA), Jon Kobashigawa (USA),Randall Starling (USA), Stuart Russell (USA), Patricia A. Uber(USA), Jayan Parameshwar (UK), Paul Mohacsi (Switzerland),Sharon Augustine (USA), Keith Aaronson (USA), Mark Barr(USA).From the International Society for Heart and Lung Transplantation,Addison, Texas.Submitted May 27, 2006; revised May 27, 2006; accepted June 16,2006.Reprint requests: Amanda Rowe, Executive Director, ISHLT, 14673MidwayRoad,Suite200,Addison,TX75001.E-mail:[email protected] Heart Lung Transplant 2006;25:1001–2.Copyright © 2006 by the International Society for Heart and LungTransplantation. 1053-2498/06/$–see front matter. doi:10.1016/j.healun.2006.06.0061001ISHLT TRANSPLANTATION GUIDELINES
--------------------------------------------------------------------------------
Page 2
(b) Task Force II—Optimal Pharmacologic and Non-phar-macologic Management of Cardiac Transplant Candidates:Approaches to Be Considered Before Transplant Evaluation:Mariell Jessup—Chair (USA), Nicholas Banner (UK), SusanBrozena (USA), Carlo Campana (Italy), Angelika Costard-Jäckle(Germany), Thomas Dengler (Germany), Sharon Hunt (USA),Marco Metra (Italy), Axel Rahmel (Germany), Dale Renlund(USA), Heather Ross (Canada), Lynne Warner Stevenson(USA).(c) Task Force III—Heart Rhythm Considerations in HeartTransplant Candidates and Considerations for VentricularAssist Devices: Edoardo Gronda—Chair (Italy), RobertBouge (USA), Maria Rosa Costanzo (USA), Mario Deng(USA), Donna Mancini (USA), Luigi Martinelli (Italy), Guill-ermo Torre-Amione (USA).II. Editorial Oversight Committee MembersMaria Rosa Costanzo—Chair (USA), Alessandro Barbone (It-aly), Ugo Livi (Italy), Manfred Hummel (Germany), DanielaPini (Italy), Salpy Pamboukian (USA), Maryl Johnson (USA),David Feldman (USA), David Taylor (USA).III. Conflict of Interest DisclosuresEach writing group member and editorial oversight commit-tee member completed a disclosure form that is maintainedon file at the ISHLT headquarters. The conflict of interestdisclosures of the task force and editorial committee chairsare as follows:Mandeep R. Mehra, MD, has reported research support,consulting fees, or is a scientific advisory board memberfor Astellas, Roche, XDx, Inc., Novartis, Scios, Medtronic,Orqis, GSK and Cardiodynamics.Mariell Jessup, MD, has reported that she is on the speaker’sbureau or has served as a consultant or is on the scientificadvisory board of GSK, Medtronic, ACORN and Ventracor.Edoardo Gronda, MD, has reported that he is on the speak-er’s bureau or has served on the scientific advisory boardof Guidant, Medtronic and Thoratec.Maria Rosa Costanzo, MD, has reported that she is on thespeaker’s bureau or has served on the scientific advisoryboard of Medtronic, Scios and CHF Solutions. In addition,she has reported that she is a shareholder and holds stockin CHF Solutions.1002 Mehra et al.The Journal of Heart and Lung Transplantation